151 related articles for article (PubMed ID: 27479786)
21. Clinical application of
Xu J; Li Y; Xu X; Zhang J; Zhang Y; Yu X; Huang D
Ann Nucl Med; 2018 Aug; 32(7):446-452. PubMed ID: 29926342
[TBL] [Abstract][Full Text] [Related]
22. Characterisation of 99mTc EDDA/HYNIC-TOC (Tektrotyd) physiological and neuroendocrine tumour uptake using SPECT/CT standardised uptake values: initial experience.
Reilly C; Gemmell AJ; McLaughlin IM; Fleming R; Reed N; McIntosh D; Nicol A
Nucl Med Commun; 2021 Aug; 42(8):935-939. PubMed ID: 33741866
[TBL] [Abstract][Full Text] [Related]
23. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience.
Hubalewska-Dydejczyk A; Fröss-Baron K; Mikołajczak R; Maecke HR; Huszno B; Pach D; Sowa-Staszczak A; Janota B; Szybiński P; Kulig J
Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1123-33. PubMed ID: 16721571
[TBL] [Abstract][Full Text] [Related]
24. Comparison of 99mTc-HYNIC-TOC and HYNIC-TATE octreotide scintigraphy with FDG PET and 99mTc-MIBI in local recurrent or distant metastatic thyroid cancers.
Sager S; Kabasakal L; Halac M; Maecke H; Uslu L; Önsel Ç; Kanmaz B
Clin Nucl Med; 2013 May; 38(5):321-5. PubMed ID: 23531772
[TBL] [Abstract][Full Text] [Related]
25. 99mTc-HYNIC-TOC imaging in the evaluation of pancreatic masses which are potential neuroendocrine tumors.
Qiao Z; Zhang J; Jin X; Huo L; Zhu Z; Xing H; Li F
Clin Nucl Med; 2015 May; 40(5):397-400. PubMed ID: 25706799
[TBL] [Abstract][Full Text] [Related]
26. Predictive Value of 99MTC-hynic-toc Scintigraphy in Lung Neuroendocrine Tumor Diagnosis.
Boutsikou E; Porpodis K; Chatzipavlidou V; Hardavella G; Gerasimou G; Domvri K; Papadopoulos N; Avramidou V; Spyratos D; Kontakiotis T; Zarogoulidis K
Technol Cancer Res Treat; 2019 Jan; 18():1533033819842586. PubMed ID: 31079574
[TBL] [Abstract][Full Text] [Related]
27. Two peptide receptor ligands (99m)Tc-EDDA/HYNIC-Tyr(3)-octreotide and (99m)Tc-EDDA/HYNIC-(D)Glu-octagastrin for scintigraphy of medullary thyroid carcinoma.
Kosowicz J; Mikołajczak R; Czepczyński R; Ziemnicka K; Gryczyńska M; Sowiński J
Cancer Biother Radiopharm; 2007 Oct; 22(5):613-28. PubMed ID: 17979564
[TBL] [Abstract][Full Text] [Related]
28. 99mTc-EDDA/HYNIC-TOC somatostatin receptor scintigraphy in daily clinical practice.
Chrapko BE; Nocuń A; Gołebiewska R; Stefaniak B; Korobowicz E; Czekajska-Chehab E; Sawicki M; Polkowski WP
Med Sci Monit; 2010 Apr; 16(4):MT35-44. PubMed ID: 20357727
[TBL] [Abstract][Full Text] [Related]
29. Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors.
Grimes J; Celler A; Birkenfeld B; Shcherbinin S; Listewnik MH; Piwowarska-Bilska H; Mikolajczak R; Zorga P
J Nucl Med; 2011 Sep; 52(9):1474-81. PubMed ID: 21795364
[TBL] [Abstract][Full Text] [Related]
30. [Preliminary clinical application of 99Tcm-HYNIC-TOC imaging in somatostatin receptor-positive tumors].
Li F; Chen LB; Jing HL; Du YR; Chen F
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Oct; 25(5):563-6. PubMed ID: 14650159
[TBL] [Abstract][Full Text] [Related]
31. Improved kit formulation for preparation of (99m)Tc-HYNIC-TOC: results of preliminary clinical evaluation in imaging patients with neuroendocrine tumors.
Korde A; Mallia M; Shinto A; Sarma HD; Samuel G; Banerjee S
Cancer Biother Radiopharm; 2014 Nov; 29(9):387-94. PubMed ID: 25379612
[TBL] [Abstract][Full Text] [Related]
32. 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients.
Pfeifer A; Knigge U; Binderup T; Mortensen J; Oturai P; Loft A; Berthelsen AK; Langer SW; Rasmussen P; Elema D; von Benzon E; Højgaard L; Kjaer A
J Nucl Med; 2015 Jun; 56(6):847-54. PubMed ID: 25952736
[TBL] [Abstract][Full Text] [Related]
33. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.
Srirajaskanthan R; Kayani I; Quigley AM; Soh J; Caplin ME; Bomanji J
J Nucl Med; 2010 Jun; 51(6):875-82. PubMed ID: 20484441
[TBL] [Abstract][Full Text] [Related]
34. Influence of tumour size and uptake of 99mTc-octreotide on radio-guided surgery for neuroendocrine tumors.
Hodolic M; Fettich J; Rubello D
Minerva Endocrinol; 2009 Jun; 34(2):89-96. PubMed ID: 19471233
[TBL] [Abstract][Full Text] [Related]
35. Biokinetics and dosimetry in patients of 99mTc-EDDA/HYNIC-Tyr3-octreotide prepared from lyophilized kits.
González-Vázquez A; Ferro-Flores G; Arteaga de Murphy C; Gutiérrez-García Z
Appl Radiat Isot; 2006 Jul; 64(7):792-7. PubMed ID: 16542847
[TBL] [Abstract][Full Text] [Related]
36. [New somatostatin analogue 99mTc-HYNIC-TOC in the scintigraphic diagnosis of medullary thyroid carcinoma].
Czepczyński R; Kosowicz J; Mikołajczak R; Ziemnicka K; Gryczyńska M; Sowiński J
Pol Arch Med Wewn; 2006 Sep; 116(3):853-60. PubMed ID: 18652278
[TBL] [Abstract][Full Text] [Related]
37. Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs.
Cwikla JB; Mikolajczak R; Pawlak D; Buscombe JR; Nasierowska-Guttmejer A; Bator A; Maecke HR; Walecki J
J Nucl Med; 2008 Jul; 49(7):1060-5. PubMed ID: 18552141
[TBL] [Abstract][Full Text] [Related]
38. Clinical value of
Chen H; Li Y; Gao X; Shen X
Clin Imaging; 2018; 52():365-369. PubMed ID: 30248495
[TBL] [Abstract][Full Text] [Related]
39. Sister Mary Joseph Nodules on 99mTc HYNIC-TOC scintigraphy in patients with neuroendocrine tumors.
Jing H; Zhang Y; Li F
Clin Nucl Med; 2015 Feb; 40(2):166-8. PubMed ID: 25140559
[TBL] [Abstract][Full Text] [Related]
40. Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors.
Perri M; Erba P; Volterrani D; Lazzeri E; Boni G; Grosso M; Mariani G
Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):323-33. PubMed ID: 18480741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
